Immunotherapy, especially monoclonal antibodies, has shown efficacy in modulating the inflammatory response and controlling lipidic pathways, offering new approaches for treating atherosclerotic disease. This article reviews the scientific evidence on the use of therapeutic monoclonal antibodies in treating atherosclerotic disease. An integrative review was carried out using the protocol Whittemore and Knafl framework and the PRISMA 2020 guidelines for systematic reviews. We analyzed clinical trials using monoclonal antibody immunotherapy to treat atherosclerosis. This review used the relevant articles published in Scopus, Embase, PubMed, Cochrane, Web of Science, Scielo, BVS, and Cinhal databases. The period of publication studies that was selected was between 2015 and 2025. Results: 277 articles were identified. One hundred and 22 studies were in duplicate and were excluded. After the complete reading of the studies, only 20 clinical studies were included in this review, both randomized and nonrandomized. Monoclonal antibody immunotherapy presents an innovative approach to treating atherosclerosis by targeting inflammation and lipidic pathway factors. However, these treatments need to be thought out individually, and further research is required to optimize them, minimize risks, and address cost challenges. Combining immunotherapy with other therapies could promote a significant advancement in atherosclerosis management.
Get full access to this article
View all access options for this article.
References
1.
YoshidaWB, MaffeiFHA, RolloHA, et al.:. MAFFEI- Doenças Vasculares Periféricas, 6th ed. Guanabara Koogan, Rio de Janeiro, 2024.
SaigusaR, WinkelsH, LeyK. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol, 2020; 17(7):387–401; doi: 10.1038/s41569-020-0352-5
7.
CharoIF, RansohoffRM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med, 2006; 354(6):610–621; doi: 10.1056/NEJMra052723
8.
LutgensE, AtzlerD, DöringY, et al.Immunotherapy for cardiovascular disease. Eur Heart J, 2019; 40(48):3937–3946; doi: 10.1093/eurheartj/ehz283
9.
PopaC, NeteaMG, van RielPL, et al.The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res, 2007; 48(4):751–762; doi: 10.1194/jlr.R600021-JLR200
10.
SlívaJ, CharalambousC, BultasJ, et al.A new strategy for treating atherothrombosis—inhibition of inflammation. Physiol Res, 2019; 68(Suppl 1):S17–S30; doi: 10.33549/physiolres.934327
11.
RakocevicJ, DobricM, BorovicML, et al.Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand? Rev Cardiovasc Med, 2023; 24(1):10; doi: 10.31083/j.rcm2401010
LiberatiA, AltmanDG, TetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med, 2009; 6(7):e1000100; doi: 10.1371/journal.pmed.1000100Doi
14.
SouzaMT, SilvaAMD, CarvalhoR. Integrative review: What is it? How to do it? Einstein (Sao Paulo), 2010; 8(1):102–106.
15.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med, 2021; 18(3):e1003583; doi: 10.1371/journal.pmed.1003583
16.
RidkerPM, HowardCP, WalterV, et al.; CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation, 2012; 126(23):2739–2748; doi: 10.1161/CIRCULATIONAHA.112.122556
17.
RidkerPM, EverettBM, ThurenT, et al.; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377(12):1119–1131; doi: 10.1056/NEJMoa1707914
18.
RussellKS, YatesDP, KramerCM, et al.A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. Vasc Med, 2019; 24(5):414–421; doi: 10.1177/1358863X19859072
19.
SabatineMS, GiuglianoRP, KeechAC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376(18):1713–1722; doi: 10.1056/NEJMoa1615664
20.
SabatineMS, GiuglianoRP, WiviottSD, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015; 372(16):1500–1509; doi: 10.1056/NEJMoa1500858
21.
BlomDJ, HalaT, BologneseM, et al.; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med, 2014; 370(19):1809–1819; doi: 10.1056/NEJMoa1316222
22.
NissenSE, StroesE, Dent-AcostaRE, et al.; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA, 2016; 315(15):1580–1590; doi: 10.1001/jama.2016.3608
23.
SchwartzGG, SzarekM, JukemaJW, et al.Risk of Incident diabetes related to lipoprotein(a), ldl cholesterol, and their changes with alirocumab: Post hoc analyses of the odyssey outcomes randomized trial. Diabetes Care, 2025; 48(4):596–604; doi: 10.2337/dc24-2110
24.
MoriartyPM, JacobsonTA, BruckertE, et al.Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol, 2014; 8(6):554–561; doi: 10.1016/j.jacl.2014.09.007
25.
ZahgerD, SchwartzGG, DuW, et al.; ODYSSEY OUTCOMES Investigators. Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome. J Am Coll Cardiol, 2024; 84(11):994–1006; doi: 10.1016/j.jacc.2024.06.035
26.
YokoteK, SuzukiA, LiY, et al.Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects. Int J Clin Pharmacol Ther, 2019; 57(12):575–589; doi: 10.5414/CP203418
27.
RidkerPM, RevkinJ, AmarencoP, et al.; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med, 2017; 376(16):1527–1539; doi: 10.1056/NEJMoa1701488
28.
RidkerPM, TardifJC, AmarencoP, et al.; SPIRE Investigators. Lipid-Reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med, 2017; 376(16):1517–1526; doi: 10.1056/NEJMoa1614062
29.
YamadaZ, MuraokaS, KawazoeM, et al.Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study. Arthritis Res Ther, 2024; 26(1):87; doi: 10.1186/s13075-024-03323-8
30.
RidkerPM, DevalarajaM, BaeresFMM, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, 2021 May 29;397(10289):2060–2069; doi: 10.1016/S0140-6736(21)00520-1
31.
RidkerPM, RaneM. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res, 2021; 128(11):1728–1746; doi: 10.1161/CIRCRESAHA.121.319077
32.
DeweyFE, GusarovaV, DunbarRL, et al.Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med, 2017; 377(3):211–221; doi: 10.1056/NEJMoa1612790
33.
RaalFJ, RosensonRS, ReeskampLF, et al.; ELIPSE HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med, 2020; 383(8):711–720; doi: 10.1056/NEJMoa2004215
34.
GaudetD, GipeDA, PordyR, et al.ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med, 2017; 377(3):296–297; doi: 10.1056/NEJMc1705994
35.
Harada-ShibaM, AliS, GipeDA, et al.A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis, 2020; 314:33–40; doi: 10.1016/j.atherosclerosis.2020.10.013
36.
RosensonRS, BurgessLJ, EbenbichlerCF, et al.Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med, 2020; 383(24):2307–2319; doi: 10.1056/NEJMoa2031049
37.
WongND, TothPP, AmsterdamEA, American Society for Preventive Cardiology. Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends Cardiovasc Med, 2021; 31(1):49–56; doi: 10.1016/j.tcm.2019.11.013
TsioufisP, TheofilisP, TsioufisK, et al.The impact of cytokines in coronary atherosclerotic plaque: Current therapeutic approaches. Int J Mol Sci, 2022; 23(24):15937; doi: 10.3390/ijms232415937
